Biostax Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTAX research report →
About the company
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).
- CEO
- Noreen Griffin
- IPO
- 2010
- Employees
- 4
- HQ
- Winter Park, FL, US
Price Chart
- Market Cap
- $7.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 67.11%
- ROIC
- 43.69%
- Revenue
- $0 · 0.00%
- Net Income
- $-2,362,647 · 33.18%
- EPS
- $-0.03 · 70.00%
- Op Income
- $-1,484,950
- FCF YoY
- 62.28%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.73
- Avg Volume
- 4
Get TickerSpark's AI analysis on BTAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BTAX coverage
Recent articles, reports, and earnings notes.
No research on BTAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTAX report →Similar companies
Peers in the same neighborhood.